Symbol
| TFRC
| contributors: mct/npt/pgu - updated : 10-09-2017
|
HGNC name
| transferrin receptor (p90, CD71)
|
HGNC id
| 11763
|
corresponding disease(s)
|
IMD46
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
|  
| gain of function
|
in hepatoma cells due to a combination of iron deficiency and chemical hypoxia | tumoral
|  
|  
| --over
|  
|
highly expressed in glioblastomas and associated with shorter survival ( | |
Variant & Polymorphism
|
| |
Candidate gene
Marker
| it can be reliably used as an independent erythroid marker for immunohistochemical analysis of the marrow | Therapy target
|
System | Type | Disorder | Pubmed |
neurology | neurodegenerative | | |
drugs that increase TFRC palmitoylation, are possible therapeutic approaches in the treatment of NBIA and also in more common neurodegenerative disorders, including Parkinson disease, where brain iron accumulation is also reported | blood | hemoglobin | | |
erythroid-progenitor-targeted gene therapy using bifunctional TFRC Ligand-Peptides in erythropoietic protoporphyria |
| | |
| mice lacking Tfr1 in the heart died in the second week of life and had cardiomegaly, poor cardiac function, failure of mitochondrial respiration, and ineffective mitophagy |